Insulin Delivery Devices Market (By Type: Insulin Pumps, Insulin Pens, Insulin Pen needles, Insulin Jet Injectors, Insulin Syringes, Others; By Application: Type I Diabetes, Type II Diabetes; By End User: Home Care, Hospitals & clinics, Others; By Distribution Channels: Online Sales, Hospital Pharmacies, Retail Pharmacies, Other Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030


The global insulin delivery devices market size was accounted at US$ 16.41 billion in 2021 and it is expected to hit around US$ 29.1 billion by 2030, poised to grow at a CAGR of 6.57% during the forecast period 2022 to 2030.

Insulin Delivery Devices Market Size 2021 to 2030

There are many ways in order to administer insulin to a patient. It is a hormone that helps in regulating the blood sugar levels of the diabetic patients. This hormone can be administered by the way of pens, pumps, jet sprays and syringes. The growing prevalence of diabetes is an important factor for the growth of the market. It also happens to be a major reason for surging mortality rate. It's about 1.5 million deaths due to diabetes in 2019 according to the report of the World Health Organization. The diabetic patients use the available insulin delivery devices in order to access the insulin dose which helps in regulating the hormone by maintaining the blood sugar of the patient. Administering insulin in the form of up tablet is also not possible as it gets degenerated by the digestive enzymes. Therefore there are a wide range of devices that are used in order to deliver the insulin at the correct location.

During the pandemic the patients with comorbidity contracted the disease earlier. About 40% of the hospitals has diabetic patients suffering with COVID-19. There were disruptions in the supply chain, shipping delays and shut down of various manufacturing units.

Growth Factors

The increasing prevalence of diabetes which is mainly due to obesity, aging or unhealthy lifestyle is expected to help in the growth of the market. Obesity happens to be the major factor causing diabetes. The number of diabetic patients across the world is increasing mainly in the obese or overweight patients. The diabetes off lifted population in the nations is driving the market for the insulin delivery devices. There's an increased demand for these devices due to various innovations. As an increasing expenditure on diabetes care the market for the insulin delivery devices is expected to grow. Due to the favorable reimbursement policies another option of other facilitative initiatives are helping in the growth of the market. The progressive and the chronic nature of diabetes inflicts the use of insulin over a long period of time. The pandemic has also proven to be a great factor in the expansion of insulin delivery devices market. As the population afflicted with diabetes across the globe is increasing it is driving the market for the Insulin delivery devices.

Report Scope of the Insulin Delivery Devices Market

Report Coverage Details
Market Size by 2030 USD 29.1 Billion
Growth Rate from 2022 to 2030

CAGR of 6.57%

North America Market Share in 2021 38%
Home Care Segment Market Share in 2021 49%
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Type, Application, End User, Distribution Channels, Geography
Companies Mentioned Novo Nordisk A/S, Wockhardt Ltd., Medtronic, F. Hoffmann-La Roche, Ltd., Abbott Laboratories, Sanofi, Eli Lilly and Company, Biocon Ltd., Ypsomed AG, Becton, Dickinson and Company, Key market developments

 

Horrifying and Unhealthy Lifestyle

The major factor contributing in the reduced degrees of actual work is the enlargement of the motorization and the urbanization. According the World Health Organization (WHO), approximately over the 60% of the global population is not satisfactorily energetic. WHO states that the active work is the livelihood component and subsequently, at every point in life, it procures any condition related to the health, inclusive of diabetes and cardiovascular disorders. The risk of diabetes type 2 arises when an individual’s weight starts increasing at an every stage of the age. Obesity affected diabetes is much more harmful than the one with an ordinary weight. 

Horrifying routines of the food consumption and smoking are the unhealthy ways of livelihood. These habits increase the risk of diabetes type 2. Work culture primarily night shift culture is one the major reasons behind the risk factors of diabetes type 2. Smoking of cigarettes should also be avoided as it has more propensity of being diseased with diabetes type 2 than the non-smokers.

Evolution of Do It Yourself (DIY) Devices

The technologies related to diabetes have been revolutionizing at a very fast pace over the last decade in order to enhance the quality of life and to expand durability of subjects with diabetes. Many of these readily available devices were too costly to afford, in spite of having admirable advancements between them. Moreover, these devices were incorporated with several issues such as infusion set management, user friendliness, blockages of cannula, and Bluetooth connectivity. There is still a race to pursue appropriate and user friendly system going on. Developments in pumps, Continuous Glucose Monitors (CGMs), prognostics procedures are able to make shut loop system possible physiologically with more than 90% to 95 % Terminal Intervention Ration (TIR) and less time invested in glucose deficiency disorder. Do It Yourself-Artificial Pancreas System (DIY-APS) has shared a few of the promising witnesses. This Do It Yourself (DIY) evolution has induced all the producers of devices to unveil Angiotensin-Converting Enzyme (ACE) pumps and harmonious sensors. However, the main goal of these manufacturers is to create artificial pancreas which will be able to have 100% TIR and no time beneath range and should be afforded by everyone. This factor has the propensity to change the diabetic therapeutics, though this work demands dedication and time. 

The beginning of systems with closed loop has become a breakthrough advancement in the treatment of diabetes. Despite this, compulsory procedures of regulations and clinical trials for the universalization of artificial pancreas systems (APS) are complicated and take a lot of time. As a result of this, patients suffering from diabetes and their care givers came together on the online platform with the hashtag “WEARENOTWAITING” to convey their understanding of the open sources software and hardware solutions. This hashtag was the emergence of DIY-APS move. This initiative was the grabbing moment for the IT specialists and enthusiasts who started working on building their own systems containing closed loop which is also known as looping. These devices are called DIY-APS. Open, Loop, and Android are its three different types. These projects related to devices were shared on the digital platforms like NightScout, Facebook, GitHub, and Twitter by the community of diabetic enthusiasts. Which in turn took these projects towards the confluence. Unlawful algorithms were made by FIY-APS for its usage to transmute CGM data as well as count doses of insulin, pumps of insulin, and communication devices approved by FDA. The algorithm used by these systems is not authorized, they are not approved by FDA, and not even regularized or commercialized. One such invention is done by Pete Schwamb for the usage of his own daughter Riley who was suffering from type 1 diabetes. The name of that evolution was “RileyLink”. This device is a translator that allows smooth communication in between iPhone and the insulin pump.

Product Insights

The insulin pen segment accounted largest market share 37% in 2021. The insulin pens segment shall have the highest market share as there's an increasing preference due to the various benefits that it offers. These insulin pens are available at affordable cost and they are technologically advanced among all the other devices. Many people across the globe prefer insulin pen as it is easy to use and it also limits the financial burden of the patient as it is pocket friendly.

In the future the development of smart pen is also expected to drive the market of the insulin pen. The increasing number of diabetic patients are using insulin pen due to the convenience in usage. Other products like the insulin pump or the hand syringes are also used to administer insulin. All of these delivery devices also share a good market growth during the forecast.

End User Insights

The home care segment accounted market share 49% in 2021. As does an increasing adoption of the delivery devices by the diabetic patients in the home care settings the market is expected to grow well during the forecast period across all the nations. As diabetes is a chronic disease which keeps on growing with every passing year it poses a great health care expenditure. The increasing pressure to reduce these expenses helps in adopting the devices which are easy to use in the homecare settings.

Insulin Delivery Devices Market Share, By End User, 2021 (%)

Significant advancements in these devices and the availability helps in driving the market beaded does a higher option rate of the smart insulin pen in the home care settings. It has a supporting smartphone application and a reusable injector pen which is extremely efficient in managing the delivery of insulin. As there is an increased awareness amongst the patient regarding the insulin delivery devices for home use the market shall grow during the forecast period.

The hospital segment has garnered revenue share of around 30% in 2021.

Distribution Channel Insights

On the basis of the distribution channel, the incident delivery devices have maximum sales through the ecommerce segment. Due to advanced features provided by the ecommerce industry and as there is an increased use of the online services by the patients, this distribution segment is expected to grow well during the forecast. Ordering the devices online and getting it delivered to the house provides convenience. Apart from the E commerce segment the hospital pharmacies and the retail pharmacies segments are also expected to have a good crowd during the forecast period.

Regional Insights

The North American region has dominated the market of the insulin delivery devices in 2021 and has garnered market share 38%. An increasing diabetic population and availability of technologically advanced devices across the North American region is helping in the growth of the market. The increasing patient base of diabetes is expected to boost the growth of the market in this region.

Insulin Delivery Devices Market Share, By Region, 2021 (%)

The market for insulin delivery devices in the Asia Pacific region is also expected to grow fast during the forecast period. In many developing economies like India and China there shall be the highest growth other than increasing population based suffering from diabetes and the awareness about the treatments for the same. Another major factor contributing to the growth in the Asia Pacific region is the high end products that are available in the market in order to treat diabetes.

By product, china insulin delivery devices market was valued at US$ 843.4 million in 2021.

Positive Impact of the Pandemic for the expansion of Insulin Delivery Devices

The impact of COVID-19 pandemic was devastating for almost all the industries across the globe. However, the global insulin delivery devices market witnessed a positive impact of this pandemic. One of the major factors behind this affirmative impact was the growing population of diabetics and increasing obesity. The demand for protective equipment involving insulin delivery devices like insulin pumps, pens, syringes, among others suddenly got a boost due to the outbreak situation of this pandemic. This pandemic created a major threat among populace which is also the factor for the increasing demand of protective equipment, thus directing towards the growth of revenue trajectory of this market. In the expansion of insulin delivery devices, COVID-19 pandemic plays a very considerable role in the year 2020. In addition, prominent market players operating in this market have taken an advantage of this positive impact to streamline their revenues and expand their footprints in various parts of the globe.

Key market players of the insulin delivery devices market

  • Novo Nordisk A/S
  • Wockhardt Ltd.
  • Medtronic
  • F. Hoffmann-La Roche, Ltd.
  • Abbott Laboratories
  • Sanofi
  • Eli Lilly and Company
  • Biocon Ltd.
  • Ypsomed AG
  • Becton, Dickinson and Company

Key market developments

  • In March 2022, Novo Nordisk announced the launch of its smart insulin in the UK. This novel product launch will offer competitive advantage and strengthen its industrial position in the UK region.
  • Medtronic launched the InPen smart insulin pen that is integrated with real-time Guardian Connect CGM data which offers real-time glucose readings coupled with insulin dose data and makes it easier to make smarter dosing decisions. This product launch assisted the company in driving the sales & revenue generation in insulin delivery devices market.

Segments covered in the report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Type

  • Insulin Pumps
    • Tubed/Tethered
    • Tubeless
  • Insulin Pens
    • Reusable
    • Disposable
  • Insulin Pen needles
    • Standard
    • Safety
  • Insulin Jet Injectors
  • Insulin Syringes
  • Others

By Application

  • Type I Diabetes
  • Type II Diabetes 

By End User

  • Home Care
  • Hospitals & clinics
  • Others

By Distribution Channels

  • Online Sales
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Clinics

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

What is the current size of insulin delivery devices market?
The global insulin delivery devices market size was reached at US$ 16.41 billion in 2021 and it is anticipated to rake around US$ 29.1 billion by 2030.
The global insulin delivery devices market is expected to drive growth at a CAGR of 6.57% from 2022 to 2030.
The major players operating in the insulin delivery devices market are Novo Nordisk A/S, Wockhardt Ltd., Medtronic, F. Hoffmann-La Roche, Ltd., Abbott Laboratories, Sanofi, Eli Lilly and Company, Biocon Ltd., Ypsomed AG, Becton, Dickinson and Company.
The increasing prevalence of diabetes which is mainly due to obesity, aging or unhealthy lifestyle is expected to help in the growth of the market.
The North American region has dominated the insulin delivery devices market in 2021 and will lead in the near future.
  • Report Code:1802
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Status:Published

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample